Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1399754

Investigating Tumor Immunogenicity in Breast Cancer: Deciphering the Tumor Immune Response to Enhance Therapeutic Approaches

Provisionally accepted
Oumayma Naji Oumayma Naji 1Amina GHOUZLANI Amina GHOUZLANI 2Soumaya Rafii Soumaya Rafii 1Dr Rizwan Sadiqi Dr Rizwan Sadiqi 3Abdou- Samad Kone Abdou- Samad Kone 1Zakia Harmak Zakia Harmak 1Khalil Choukri Khalil Choukri 1Sarah Kandoussi Sarah Kandoussi 1Mehdi KARKOURI Mehdi KARKOURI 4Abdallah Badou Abdallah Badou 5*
  • 1 Immuno-Genetics and Human Pathology Laboratory (LIGEP), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco, Casablanca, Morocco
  • 2 Huntington Medical Research Institutes, Pasadena, California, United States
  • 3 Faculty of Science and Technology, Middlesex University London, London, United Kingdom
  • 4 Department of Pathological Anatomy, Ibn Rochd University Hospital Center, Casablanca, Morocco, Casablanca, Morocco
  • 5 Département des Sciences Naturelles, Immuno-Genetics and Human Pathology Laboratory (LIGEP), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco, Casablanca, Morocco

The final, formatted version of the article will be published soon.

    The interplay between immune cells and malignant cells represents an essential chapter in the eradication of breast cancer. This widely distributed and diverse form of cancer represents a major threat to women worldwide. The incidence of breast cancer is related to several risk factors, notably genetic predisposition and family antecedents. Despite progress in treatment modalities varying from surgery and chemotherapy to radiotherapy and targeted therapies, persistently high rates of recurrence, metastasis, and treatment resistance underscore the urgent need for new therapeutic approaches.Immunotherapy has gained considerable ground in the treatment of breast cancer, as it takes advantage of the complex interactions within the tumor microenvironment. This dynamic interplay between immune and tumor cells has become a key point of focus in immunological research. This study investigates the role of various cancer markers, such as neoantigens and immune regulatory genes, in the diagnosis and treatment of breast tumors. Moreover, it explores the future potential of immune checkpoint inhibitors as therapeutically effective agents, as well as the challenges that prevent their efficacy, in particular tumorinduced immunosuppression and the difficulty of achieving tumor specificity.

    Keywords: breast cancer, Immune microenviroment, Immune Response --, therapy resistance, Immunotherapy

    Received: 12 Mar 2024; Accepted: 18 Sep 2024.

    Copyright: © 2024 Naji, GHOUZLANI, Rafii, Sadiqi, Kone, Harmak, Choukri, Kandoussi, KARKOURI and Badou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Abdallah Badou, Département des Sciences Naturelles, Immuno-Genetics and Human Pathology Laboratory (LIGEP), Faculty of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco, Casablanca, Morocco

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.